Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells

Cancer Gene Therapy volume 14, pages 327–334 (2007)Cite this article

Abstract

Gene therapy of cancer using adenovirus as a single treatment modality has met limited success and efforts to enhance therapeutic outcomes have included combination of gene therapy with chemotherapy. The goal of this study was to investigate which chemotherapeutic agents may be suitable for combination with gene therapy of prostate cancer. Using an adenovirus expressing green fluorescent protein (GFP), we determined the effect of cisplatin, gemcitabine, doxorubicin, depsipeptide and MS-275 on adenoviral infectivity and transgene expression in LNCaP cells. We found that the two histone deacetylase inhibitors (HDACi), depsipeptide and MS-275, and to a lesser extent doxorubicin, increased infectivity and transgene expression. However, only the HDACi selectively increased infectivity in LNCaP cells while doxorubicin increased infectivity to a greater extent in normal prostate epithelial cells (PrEC). The increase in infectivity but not transgene expression correlated to increased surface expression of coxsackie and adenovirus receptor (CAR). Increased transgene expression following infection with an adenovirus expressing tumor necrosis factor-related apoptosis inducing ligand (TRAIL) was observed only in LNCaP cells treated with depsipeptide or MS-275. Combination of TRAIL gene therapy with HDACi but not doxorubicin resulted in increased induction of apoptosis in LNCaP cells. In contrast, apoptosis was not enhanced by HDACi in normal PrEC. These results suggest that combination of HDACi with adenoviral TRAIL gene therapy may be a new therapeutic approach for the treatment of prostate cancer that warrants further investigation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Greber UF . Signalling in viral entry. Cell Mol Life Sci 2002; 59: 608–626.

    Article  CAS  PubMed  Google Scholar 

  2. Korn WM, Macal M, Christian C, Lacher MD, McMillan A, Rauen KA et al. Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation. Cancer Gene Ther 2006; 13: 792–797.

    Article  CAS  PubMed  Google Scholar 

  3. Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59: 325–330.

    CAS  PubMed  Google Scholar 

  4. Marsee DK, Vadysirisack DD, Morrison CD, Prasad ML, Eng C, Duh QY et al. Variable expression of coxsackie-adenovirus receptor in thyroid tumors: implications for adenoviral gene therapy. Thyroid 2005; 15: 977–987.

    Article  CAS  PubMed  Google Scholar 

  5. Matsumoto K, Shariat SF, Ayala GE, Rauen KA, Lerner SP . Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology 2005; 66: 441–446.

    Article  PubMed  Google Scholar 

  6. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000; 18: 609–622.

    Article  CAS  PubMed  Google Scholar 

  7. Anderson WF . Gene therapy scores against cancer. Nat Med 2000; 6: 862–863.

    Article  CAS  PubMed  Google Scholar 

  8. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM . A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 2000; 7: 588–592.

    Article  CAS  PubMed  Google Scholar 

  9. Jacob D, Davis JJ, Zhang L, Zhu H, Teraishi F, Fang B . Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther 2005; 12: 109–115.

    Article  CAS  PubMed  Google Scholar 

  10. Kelley JR, Fraser MM, Hubbard JM, Watson DK, Cole DJ . CaSm antisense gene therapy: a novel approach for the treatment of pancreatic cancer. Anticancer Res 2003; 23: 2007–2013.

    CAS  PubMed  Google Scholar 

  11. Triplett JW, Herring BP, Pavalko FM . Adenoviral transgene expression enhanced by cotreatment with etoposide in cultured cells. Biotechniques 2005; 39: 826, 828, 830, passim.

    Article  CAS  PubMed  Google Scholar 

  12. Sachs MD, Ramamurthy M, Poel H, Wickham TJ, Lamfers M, Gerritsen W et al. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther 2004; 11: 477–486.

    Article  CAS  PubMed  Google Scholar 

  13. Pong RC, Lai YJ, Chen H, Okegawa T, Frenkel E, Sagalowsky A et al. Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. Cancer Res 2003; 63: 8680–8686.

    CAS  PubMed  Google Scholar 

  14. El-Zawahry A, Lu P, White SJ, Voelkel-Johnson C . In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL. Cancer Gene Ther 2006; 13: 281–289.

    Article  CAS  PubMed  Google Scholar 

  15. MacFarlane M . TRAIL-induced signalling and apoptosis. Toxicol Lett 2003; 139: 89–97.

    Article  CAS  PubMed  Google Scholar 

  16. Voelkel-Johnson C, King DL, Norris JS . Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 2002; 9: 164–172.

    Article  CAS  PubMed  Google Scholar 

  17. Piekarz R, Bates S . A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 2004; 10: 2289–2298.

    Article  CAS  PubMed  Google Scholar 

  18. Rubinchik S, Ding R, Qiu AJ, Zhang F, Dong J . Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system. Gene Ther 2000; 7: 875–885.

    Article  CAS  PubMed  Google Scholar 

  19. Earel Jr JK, VanOosten RL, Griffith TS . Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res 2006; 66: 499–507.

    Article  CAS  PubMed  Google Scholar 

  20. VanOosten RL, Moore JM, Karacay B, Griffith TS . Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biol Ther 2005; 4: 1104–1112.

    Article  CAS  PubMed  Google Scholar 

  21. Goldsmith ME, Kitazono M, Fok P, Aikou T, Bates S, Fojo T . The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells. Clin Cancer Res 2003; 9: 5394–5401.

    CAS  PubMed  Google Scholar 

  22. Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M, Oft M et al. Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res 2006; 66: 1648–1657.

    Article  CAS  PubMed  Google Scholar 

  23. Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT . The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 2000; 60: 5031–5036.

    CAS  PubMed  Google Scholar 

  24. Okegawa T, Pong RC, Li Y, Bergelson JM, Sagalowsky AI, Hsieh JT . The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Res 2001; 61: 6592–6600.

    CAS  PubMed  Google Scholar 

  25. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T . Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004; 23: 6261–6271.

    Article  CAS  PubMed  Google Scholar 

  26. Vanoosten RL, Moore JM, Ludwig AT, Griffith TS . Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 2005; 11: 542–552.

    Article  CAS  PubMed  Google Scholar 

  27. Singh TR, Shankar S, Srivastava RK . HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005; 24: 4609–4623.

    Article  CAS  PubMed  Google Scholar 

  28. Zhang XD, Gillespie SK, Borrow JM, Hersey P . The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol 2003; 66: 1537–1545.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant from the NIH/NCI CA102218.

Author information

Authors and Affiliations

  1. Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, SC, USA

    L Kasman, P Lu & C Voelkel-Johnson

Authors
  1. L Kasman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Voelkel-Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Voelkel-Johnson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kasman, L., Lu, P. & Voelkel-Johnson, C. The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther 14, 327–334 (2007). https://doi.org/10.1038/sj.cgt.7701017

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7701017

Keywords

This article is cited by

Search

Advanced search

Quick links